Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized MAV regimen based on bone marrow proliferation for AML
ChiCTR2400091871Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone-liposome, cytarabine and venetoclax in acute myeloid leukemia (AML), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Safety. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
mitoxantrone-liposomecytarabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400091871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091871.